» Articles » PMID: 24062559

Quantitative Imaging in Cancer Evolution and Ecology

Overview
Journal Radiology
Specialty Radiology
Date 2013 Sep 25
PMID 24062559
Citations 229
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer therapy, even when highly targeted, typically fails because of the remarkable capacity of malignant cells to evolve effective adaptations. These evolutionary dynamics are both a cause and a consequence of cancer system heterogeneity at many scales, ranging from genetic properties of individual cells to large-scale imaging features. Tumors of the same organ and cell type can have remarkably diverse appearances in different patients. Furthermore, even within a single tumor, marked variations in imaging features, such as necrosis or contrast enhancement, are common. Similar spatial variations recently have been reported in genetic profiles. Radiologic heterogeneity within tumors is usually governed by variations in blood flow, whereas genetic heterogeneity is typically ascribed to random mutations. However, evolution within tumors, as in all living systems, is subject to Darwinian principles; thus, it is governed by predictable and reproducible interactions between environmental selection forces and cell phenotype (not genotype). This link between regional variations in environmental properties and cellular adaptive strategies may permit clinical imaging to be used to assess and monitor intratumoral evolution in individual patients. This approach is enabled by new methods that extract, report, and analyze quantitative, reproducible, and mineable clinical imaging data. However, most current quantitative metrics lack spatialness, expressing quantitative radiologic features as a single value for a region of interest encompassing the whole tumor. In contrast, spatially explicit image analysis recognizes that tumors are heterogeneous but not well mixed and defines regionally distinct habitats, some of which appear to harbor tumor populations that are more aggressive and less treatable than others. By identifying regional variations in key environmental selection forces and evidence of cellular adaptation, clinical imaging can enable us to define intratumoral Darwinian dynamics before and during therapy. Advances in image analysis will place clinical imaging in an increasingly central role in the development of evolution-based patient-specific cancer therapy.

Citing Articles

Magnetic resonance diffusion-derived vessel density (DDVD) as a valuable tissue perfusion biomarker for isocitrate dehydrogenase genotyping in diffuse gliomas.

Ni C, Lin R, Yao D, Ma F, Shi Y, He Y BMC Med Imaging. 2025; 25(1):79.

PMID: 40050759 PMC: 11887403. DOI: 10.1186/s12880-025-01605-4.


The radiogenomic and spatiogenomic landscapes of glioblastoma and their relationship to oncogenic drivers.

Kazerooni A, Akbari H, Hu X, Bommineni V, Grigoriadis D, Toorens E Commun Med (Lond). 2025; 5(1):55.

PMID: 40025245 PMC: 11873127. DOI: 10.1038/s43856-025-00767-0.


Revolutionizing HER-2 assessment: multidimensional radiomics in breast cancer diagnosis.

Xie H, Tan T, Li Q, Li T BMC Cancer. 2025; 25(1):265.

PMID: 39953417 PMC: 11829378. DOI: 10.1186/s12885-025-13549-7.


Preoperative prediction of IDH genotypes and prognosis in adult-type diffuse gliomas: intratumor heterogeneity habitat analysis using dynamic contrast-enhanced MRI and diffusion-weighted imaging.

Wang X, Xie Z, Wang X, Song Y, Suo S, Ren Y Cancer Imaging. 2025; 25(1):11.

PMID: 39923105 PMC: 11807326. DOI: 10.1186/s40644-025-00829-5.


Prediction of early postoperative recurrence of hepatocellular carcinoma by habitat analysis based on different sequence of contrast-enhanced CT.

Zhang Y, Ma H, Lei P, Li Z, Yan Z, Wang X Front Oncol. 2025; 14():1522501.

PMID: 39830646 PMC: 11739309. DOI: 10.3389/fonc.2024.1522501.


References
1.
Goh V, Ganeshan B, Nathan P, Juttla J, Vinayan A, Miles K . Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology. 2011; 261(1):165-71. DOI: 10.1148/radiol.11110264. View

2.
Kern S . Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res. 2012; 72(23):6097-101. PMC: 3513583. DOI: 10.1158/0008-5472.CAN-12-3232. View

3.
Tixier F, Rest C, Hatt M, Albarghach N, Pradier O, Metges J . Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011; 52(3):369-78. PMC: 3789272. DOI: 10.2967/jnumed.110.082404. View

4.
Channin D, Mongkolwat P, Kleper V, Rubin D . The Annotation and Image Mark-up project. Radiology. 2009; 253(3):590-2. DOI: 10.1148/radiol.2533090135. View

5.
Yang X, Knopp M . Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging: a review. J Biomed Biotechnol. 2011; 2011:732848. PMC: 3085501. DOI: 10.1155/2011/732848. View